Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 6, 2022 20:59 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 983 | $268.36 | $263,797.88 |
DisclosureSEC source: 0000899243-22-014117 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.36 (range $267.97 to $268.81). Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:59 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 917 | $267.23 | $245,049.91 |
DisclosureSEC source: 0000899243-22-014117 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,858 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.85 to $267.79). Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:59 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 100 | $265.83 | $26,583.00 |
DisclosureSEC source: 0000899243-22-014117 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,775 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:59 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 2,000 | $81.54 | $163,080.00 |
DisclosureSEC source: 0000899243-22-014117 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:02 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 257 | $268.43 | $68,986.51 |
DisclosureSEC source: 0000899243-22-014120 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,506 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78). Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:02 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 305 | $267.10 | $81,465.50 |
DisclosureSEC source: 0000899243-22-014120 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,763 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 1,344 | $263.09 | $353,592.96 |
DisclosureSEC source: 0000899243-22-013705 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,068 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 223 | $266.68 | $59,469.64 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,620 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $266.68 (range $266.55 to $266.83). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 536 | $265.95 | $142,549.20 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,843 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $265.95 (range $265.55 to $266.47). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 1,142 | $265.06 | $302,698.52 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $265.06 (range $264.53 to $265.48). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 381 | $263.67 | $100,458.27 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,521 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $263.67 (range $263.45 to $264.42). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 300 | $261.42 | $78,426.00 |
DisclosureSEC source: 0000899243-22-013708 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,902 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $261.42 (range $261.04 to $261.80). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 137 | $263.09 | $36,043.33 |
DisclosureSEC source: 0000899243-22-013713 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,823 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
MCGLYNN MARGARET GDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 5,000 | $127.54 Strike: $127.54 | $637,700.00 |
DisclosureSEC source: 0000899243-22-013305 · doc4.xml · derivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
MCGLYNN MARGARET GDirector
|
SaleCommon Stock | 1,011 | $262.97 | $265,862.67 |
DisclosureSEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $262.97 (range $262.80 to $263.34). Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
MCGLYNN MARGARET GDirector
|
SaleCommon Stock | 2,970 | $262.37 | $779,238.90 |
DisclosureSEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $262.37 (range $261.79 to $262.78). Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
MCGLYNN MARGARET GDirector
|
SaleCommon Stock | 1,019 | $261.28 | $266,244.32 |
DisclosureSEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,080 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $261.28 (range $260.78 to $261.73). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:05 UTC |
MCGLYNN MARGARET GDirector
|
Exercise / conversionCommon Stock | 5,000 | $127.54 | $637,700.00 |
DisclosureSEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 2,122 | $250.06 | $530,627.32 |
DisclosureSEC source: 0000899243-22-011701 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,412 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $250.06 (range $250.00 to $250.48). F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:12 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 61 | $251.05 | $15,314.05 |
DisclosureSEC source: 0000899243-22-011703 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,202 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:12 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 3,110 | $250.13 | $777,904.30 |
DisclosureSEC source: 0000899243-22-011703 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,263 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $250.13 (range $250.00 to $250.61). F3 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:15 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 34 | $251.24 | $8,542.16 |
DisclosureSEC source: 0000899243-22-011705 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,356 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:15 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 2,799 | $250.10 | $700,029.90 |
DisclosureSEC source: 0000899243-22-011705 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,390 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:18 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 560 | $232.68 | $130,300.80 |
DisclosureSEC source: 0000899243-22-008109 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,077 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $232.68 (range $232.43 to $232.87). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:18 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,784 | $231.64 | $644,885.76 |
DisclosureSEC source: 0000899243-22-008109 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,637 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.64 (range $231.08 to $232.07). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:18 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,188 | $230.62 | $735,216.56 |
DisclosureSEC source: 0000899243-22-008109 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,421 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.62 (range $230.07 to $231.05). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:18 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,040 | $229.41 | $238,586.40 |
DisclosureSEC source: 0000899243-22-008109 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,609 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.41 (range $228.91 to $229.81). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 18 | $232.80 | $4,190.40 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,189 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.80 (range $232.59 to $232.92). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 87 | $231.81 | $20,167.47 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,207 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.81 (range $231.52 to $232.31). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 115 | $230.97 | $26,561.55 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,294 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $230.97 (range $230.50 to $231.47). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 77 | $230.26 | $17,730.02 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,409 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.26 (range $229.50 to $230.48). Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 28 | $228.88 | $6,408.64 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,486 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.88 (range $228.39 to $229.36). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:18 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 6,038 | $227.86 | $1,375,818.68 |
DisclosureSEC source: 0000899243-22-008109 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,649 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:19 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 7,246 | $227.86 | $1,651,073.56 |
DisclosureSEC source: 0000899243-22-008111 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,066 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:20 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 1,242 | $227.86 | $283,002.12 |
DisclosureSEC source: 0000899243-22-008112 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,823 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:21 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 7,246 | $227.86 | $1,651,073.56 |
DisclosureSEC source: 0000899243-22-008116 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,842 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:23 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 12,141 | $227.86 | $2,766,448.26 |
DisclosureSEC source: 0000899243-22-008119 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,949 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:24 UTC |
Liu JoySVP, General Counsel
|
Tax withholdingCommon Stock | 1,554 | $227.86 | $354,094.44 |
DisclosureSEC source: 0000899243-22-008120 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,454 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:25 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 7,368 | $227.86 | $1,678,872.48 |
DisclosureSEC source: 0000899243-22-008121 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,210 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:27 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 2,590 | $227.86 | $590,157.40 |
DisclosureSEC source: 0000899243-22-008123 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,514 Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:29 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 2,189 | $227.86 | $498,785.54 |
DisclosureSEC source: 0000899243-22-008128 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,373 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,038 | $233.27 | $242,134.26 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,687 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $233.27 (range $232.91 to $233.50). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 600 | $231.85 | $139,110.00 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,725 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.85 (range $231.67 to $232.01). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 385 | $231.01 | $88,938.85 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,325 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.01 (range $230.66 to $231.43). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,303 | $230.05 | $299,755.15 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,710 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.05 (range $229.65 to $230.59). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:51 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 986 | $229.22 | $226,010.92 |
DisclosureSEC source: 0000899243-22-007203 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,013 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.22 (range $228.65 to $229.60). F3 · price: Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 120 | $233.48 | $28,017.60 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,104 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $233.48 (range $233.18 to $233.73). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 80 | $232.04 | $18,563.20 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,224 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.89 to $232.13). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 101 | $230.42 | $23,272.42 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,304 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.42 (range $230.05 to $230.75). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:03 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 218 | $229.52 | $50,035.36 |
DisclosureSEC source: 0000899243-22-007216 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,405 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.52 (range $229.05 to $229.97). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.